Skip to main content

FDA Approvals

FDA Oncology Update, FDA Approvals

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Oncology Update, FDA Approvals

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

FDA Oncology Update, FDA Approvals

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

FDA Oncology Update, FDA Approvals

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

FDA Oncology Update, FDA Approvals

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Page 7 of 53
Results 61 - 70 of 527